Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Clinical trial NCT02179671 · COMPLETED
Trial details
- NCT number
- NCT02179671
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-25
- Primary completion
- 2016-06-11
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.